









Markets
/
Stocks
/
nasdaq-clsd
/

Clearside Biomedical Inc

CLSD

4.070USD

+0.370+10.00%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

21.30MMarket Cap

LossP/E TTM



Clearside Biomedical Inc

4.070

+0.370+10.00%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Clearside Biomedical Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Clearside Biomedical Inc's Score

Industry at a Glance

Industry Ranking

185 / 407

Overall Ranking

313 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Hold

Current Rating

63.000

Target Price

+1440.34%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Clearside Biomedical Inc Highlights

StrengthsRisks

Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 25.40% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.66M.

Overvalued

The company’s latest PE is -0.68, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 795.64K shares, decreasing 19.64% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 224.20K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.35.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.31, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 492.00K, representing a year-over-year increase of 446.67%, while its net profit experienced a year-over-year increase of 40.81%.

Score

Industry at a Glance

Previous score

6.31

Change



Financials

6.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.75

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.64

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.79

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.22

Key Metrics

Free cash flow

No Data

Clearside Biomedical Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 6.74, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.68, which is -91.37% below the recent high of -0.06 and -464.11% above the recent low of -3.84.

Score

Industry at a Glance

Previous score

6.74

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 185/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 6.57, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Clearside Biomedical Inc is 75.00, with a high of 90.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

6.57

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Hold

Current Rating

63.000

Target Price

+1602.70%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Clearside Biomedical Inc

CLSD

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 6.74, which is higher than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 4.26 and the support level at 3.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.52

Change

-0.78

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.131

Neutral

RSI(14)

56.703

Neutral

STOCH(KDJ)(9,3,3)

62.935

Buy

ATR(14)

0.291

High Vlolatility

CCI(14)

75.741

Neutral

Williams %R

17.857

Overbought

TRIX(12,20)

0.321

Sell

StochRSI(14)

74.940

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

3.940

Buy

MA10

3.886

Buy

MA20

3.935

Buy

MA50

3.110

Buy

MA100

1.853

Buy

MA200

1.373

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 15.20%, representing a quarter-over-quarter decrease of 44.52%. The largest institutional shareholder is The Vanguard, holding a total of 224.20K shares, representing 4.28% of shares outstanding, with 15.76% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Whitmore (Bradford T)

284.60K

-5.03%

Wiles (Stephen Boyd)

266.90K

The Vanguard Group, Inc.

Star Investors

224.20K

+19.83%

Grace Brothers Management, LLC

150.30K

-4.07%

Carmignac Gestion

100.56K

Geode Capital Management, L.L.C.

52.69K

-0.23%

BlackRock Institutional Trust Company, N.A.

41.68K

-20.55%

GSA Capital Partners LLP

35.57K

+164.66%

Renaissance Technologies LLC

Star Investors

33.11K

-10.44%

Lasezkay (George M)

25.52K

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 1.04, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.79. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.